Phased revenue model based on contracts with pharmaceutical companies
First written in FY2016. 17 of 22 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
2 other companies' latest entry also says "Other".
- FY2026Growth in analysis-service revenueAnnual report
「Income under license agreements and other arrangements 2,330 Income from analytical services and other sources 806,200 Revenue from contracts with customers 808,530」
Income from analytical services and other sources was ¥806.200 million, compared with ¥2.330 million in license income, up from ¥747.057 million in the previous fiscal year. The revenue mix continues to be centered on analytical services. - FY2026-H1RestatedAnnual report
「Income under license agreements and other arrangements 2,330 Income from analytical services and other sources 429,561 Revenue from contracts with customers 431,891」
During the interim consolidated accounting period, income from analytical services and other sources was ¥429.561 million, compared with ¥2.330 million in license income. The revenue mix continues to be centered on analytical services. - FY2025Continued revenue mix centered on analytical servicesAnnual report
「Income under license agreements and other arrangements 2,991 Income from analytical services and other sources 747,057 Revenue from contracts with customers 750,048」
Revenue for the consolidated fiscal year consisted of ¥2.991 million in income under license agreements and other arrangements and ¥747.057 million in income from analytical services and other sources. Analytical services and other sources continue to account for the core of revenue. - FY2025-H1Continued revenue mix centered on analytical servicesAnnual report
「Income under license agreements and other arrangements 2,970 Income from analytical services and other sources 222,113 Revenue from contracts with customers 225,083」
Revenue for the interim consolidated accounting period consisted of ¥2.970 million in income under license agreements and other arrangements and ¥222.113 million in income from analytical services and other sources. Analytical services and other sources continue to account for the core of revenue. - FY2024-Q2Revenue mix centered on analytical servicesAnnual report
「Income under license agreements and other arrangements 387 Income from analytical services and other sources 356,064 Revenue from contracts with customers 356,452」
Business revenue for the cumulative second quarter of the current fiscal year consisted of ¥0.387 million in income under license agreements and other arrangements and ¥356.064 million in income from analytical services and other sources. Analytical services and other sources continue to account for the core of revenue. - FY2023-Q3RestatedAnnual report
「Consolidated business revenue for the cumulative third quarter of the current fiscal year was ¥699 million, an increase of ¥364 million year on year, mainly due to income from contract testing services and the receipt of contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, consisting of income from contract testing services and contract upfront payments and other amounts, together with the receipts recorded during the current fiscal year. - FY2023-Q2RestatedAnnual report
「Consolidated business revenue for the cumulative second quarter of the current fiscal year was ¥514 million, an increase of ¥273 million year on year, mainly due to income from analytical services and other sources and the receipt of contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including analytical services revenue and contract upfront payments and other amounts, together with the receipts recorded during the quarter. - FY2023-Q1RestatedAnnual report
「Consolidated business revenue for the cumulative first quarter of the current fiscal year was ¥385 million, an increase of ¥292 million year on year, mainly due to income from analytical services and other sources and the receipt of contract upfront payments and other amounts.」
The Company is reaffirming its revenue structure, consisting of analytical services revenue and contract upfront payments and other amounts, together with the receipts recorded during the quarter. - FY2022-Q3RestatedAnnual report
「The Group earns revenue under license agreements and other arrangements that authorize third parties to research and develop, manufacture and sell pharmaceuticals and other products, and to use its technologies. This revenue consists of contract upfront payments, milestone-related income and royalty income, as well as income from analytical services and other sources.」
The Company is reaffirming its tiered revenue structure, consisting of contract upfront payments, milestones, royalties and analytical services revenue, together with an explanation of its revenue recognition methods. - FY2022-Q1RestatedAnnual report
「The Group earns revenue under license agreements and other arrangements that authorize third parties to research and develop, manufacture and sell pharmaceuticals and other products, and to use its technologies. This revenue consists of contract upfront payments, milestone-related income and royalty income, as well as income from analytical services and other sources.」
The Company is reaffirming its revenue structure, consisting of contract upfront payments, milestones, royalties and analytical services revenue, together with an explanation of its revenue recognition methods. - FY2021-Q3RestatedAnnual report
「Consolidated business revenue for the cumulative third quarter of the current fiscal year was ¥160 million, a decrease of ¥1 million year on year, mainly due to income from contract testing services and the receipt of contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and contract upfront payments and other amounts, together with the receipts recorded during the current fiscal year. - FY2021-Q2RestatedAnnual report
「Consolidated business revenue for the cumulative second quarter of the current fiscal year was ¥100 million, a decrease of ¥3 million year on year, mainly due to income from contract testing services and the receipt of initial contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and initial contract upfront payments and other amounts, together with the receipts recorded during the current fiscal year. - FY2021-Q1RestatedAnnual report
「Consolidated business revenue for the cumulative first quarter of the current fiscal year was ¥41 million, a decrease of ¥14 million year on year, mainly due to income from contract testing services and the receipt of contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and contract upfront payments and other amounts, together with the receipts recorded during the quarter. - FY2020-Q3RestatedAnnual report
「Consolidated business revenue for the cumulative third quarter of the current fiscal year was ¥161 million, a decrease of ¥86 million year on year, mainly due to income from contract testing services and the receipt of multiple contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and contract upfront payments and other amounts, together with the receipts recorded during the current fiscal year. - FY2020-Q2RestatedAnnual report
「Revenue was ¥104 million, an increase of ¥80 million year on year, mainly due to income from contract testing services and the receipt of initial contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and initial contract upfront payments and other amounts, together with the receipts recorded during the current fiscal year. - FY2020-Q1RestatedAnnual report
「Consolidated business revenue for the cumulative first quarter of the current fiscal year was ¥55 million, an increase of ¥42 million year on year, mainly due to income from contract testing services and the receipt of initial contract upfront payments and other amounts.」
The Company is reaffirming its tiered revenue structure, including income from contract testing services and initial contract upfront payments, together with the results recorded during the quarter. - FY2018RestatedAnnual report
「The Company has adopted a contractual structure under which consideration is received in stages, including upfront contract payments, research collaboration payments, development collaboration payments, milestones tied to progress in research and development, and royalties tied to sales and other factors following the launch of pharmaceutical products.」
The Company continues to use a tiered revenue model consisting of upfront payments, collaboration payments, milestones and royalties under collaboration agreements. - FY2018-Q3RestatedAnnual report
「Business revenue for the cumulative third quarter of the current fiscal year was ¥203 million, a decrease of ¥31 million year on year, mainly due to the receipt of milestones from partner pharmaceutical companies.」
The Company is reaffirming its tiered revenue model, with milestones and other payments from partner pharmaceutical companies as revenue sources, together with the receipts recorded during the current fiscal year. - FY2018-Q2RestatedAnnual report
「Business revenue for the cumulative second quarter of the current fiscal year was ¥201 million, an increase of ¥167 million year on year, mainly due to the receipt of milestones from partner pharmaceutical companies.」
The Company is reaffirming its tiered revenue model, with milestones and other payments from partner pharmaceutical companies as revenue sources, together with the receipts recorded during the current fiscal year. - FY2017RestatedAnnual report
「We will receive contract signing fees, research collaboration fees, development collaboration fees, milestones, royalties, and other payments in stages.」
The Company continues to use a tiered revenue model consisting of upfront payments, collaboration payments, milestones and royalties under collaboration agreements. - FY2017-Q3RestatedAnnual report
「Business revenue for the cumulative third quarter of the current consolidated fiscal year was ¥234 million, due to the receipt of milestones from partner pharmaceutical companies, contract analysis testing fees, and royalties from sales of research reagents and other products, an increase of ¥23 million from the same period of the previous year.」
The company reconfirms, with actual results, the structure under which milestones from partners, contract analysis testing, and royalties from sales of research reagents and other products serve as revenue sources. - FY2016First statedAnnual report
「We will receive contract signing fees, research collaboration fees, development collaboration fees, milestones, royalties, and other payments in stages.」
A revenue structure comprising contract signing fees, collaboration fees, milestones linked to development progress, and royalties after launch.